20 June 2023: Original Paper
Survival Analysis of Transplant-Associated Thrombotic Microangiopathy Under Different Diagnostic Criteria and Efficacy of Plasma Exchange
Yifan Xu 12ABCDEF , Yan Wei 12BF , Lijun Wang 2BC , Ning Lu 2BD , Yongli Wu 2BD , Liping Dou 2AF , Daihong Liu 2AF , Meng Li 2ADEF* , Chunji Gao 2ADEFG*DOI: 10.12659/AOT.939890
Ann Transplant 2023; 28:e939890
Table 3 Survival group vs deceased group.
| Characteristics | Survived (n=16) | Dead (n=16) | P value |
|---|---|---|---|
| 33.5 (3–60) | 33.5 (15–60) | 0.227 | |
| 0.126 | |||
| Male | 9 (56.2%) | 13 (81.2%) | |
| Female | 7 (43.8%) | 3 (18.8%) | |
| 0.252 | |||
| AA | 2 (12.4%) | 0 (0.0%) | |
| MDS/AML/CML | 7 (43.8%) | 11 (68.8%) | |
| ALL | 7 (43.8%) | 5 (31.2%) | |
| >0.99 | |||
| BU/CY+ATG | 14 (87.4%) | 15 (93.8%) | |
| FluCY-ATG | 1 (6.3%) | 0 (0.0%) | |
| TBI/CY/ATG | 1 (6.3%) | 1 (6.2%) | |
| >0.99 | |||
| MUD | 2 (12.5%) | 2 (12.5%) | |
| Haplo | 13 (81.3%) | 13 (81.3%) | |
| MRD | 1 (6.2%) | 1 (6.2%) | |
| >0.99 | |||
| Yes | 10 (62.5%) | 9 (56.2%) | |
| No | 6 (37.5%) | 7 (43.8%) | |
| >0.99 | |||
| ABO mismatch | 5 (31.3%) | 4 (25.0%) | |
| ABO matched | 11 (68.8%) | 12 (75.0%) | |
| 0.172 | |||
| HLA matched | 1 (6.2%) | 5 (31.2%) | |
| HLA mismatch | 15 (93.8%) | 11 (68.8%) | |
| Yes | 2 (12.5%) | 11 (68.8%) | |
| No | 14 (87.5%) | 5 (31.2%) | |
| 0.333 | |||
| Yes | 15 (93.8%) | 12 (75.0%) | |
| No | 1 (6.2%) | 4 (25.0%) | |
| 47 (22–95) | 139.5 (29–591) | ||
| Early TA-TMA | 16 (100.0%) | 7 (43.8%) | |
| Late TA-TMA | 0 (0.0%) | 9 (56.2%) | |
| Yes | 2 (12.5%) | 10 (62.5%) | |
| No | 14 (87.5%) | 6 (37.5%) | |
| 0.473 | |||
| Ye | 8 (50.0%) | 11 (68.8%) | |
| No | 8 (50.0%) | 5 (31.2%) | |
| 0.458 | |||
| Yes | 12 (75.0%) | 9 (56.2%) | |
| No | 4 (25.0%) | 7 (43.8%) | |
| Yes | 2 (12.5%) | 10 (62.5%) | |
| No | 14 (87.5%) | 6 (37.5%) | |
| 0.285 | |||
| Yes | 9 (56.2%) | 5 (31.2%) | |
| No | 7 (43.8%) | 11 (68.8%) | |
| Yes | 7 (43.8%) | 14 (87.5%) | |
| No | 9 (56.3%) | 2 (12.5%) | |
| >0.99 | |||
| Yes | 15 (93.8%) | 16 (100.0%) | |
| No | 1 (6.2%) | 0 (0.0%) | |
| Yes | 14 (87.5%) | 4 (25.0%) | |
| No | 2 (12.5%) | 12 (75.0%) | |
| 0.135 | |||
| Yes | 3 (18.8%) | 8 (50.0%) | |
| No | 13 (81.3%) | 8 (50.0%) | |
| 0.011 | |||
| Yes | 5 (31.2%) | 13 (81.2%) | |
| No | 11 (68.8%) | 3 (18.8%) | |
| TBIL (μmol/L), median | 10.9 (4.7–65.6) | 36.4 (6.5–329.0) | |
| PLT (×10/L), median | 30.5 (7–165) | 13.5 (3–72) | |
| Hb (g/L), mean | 75.3±12.0 | 64.0±12.3 | |
| Schistocyte (%), median | 1.0 (0.0–2.6) | 1.8 (0.0–4.0) | 0.166 |
| LDH (U/L), median | 333.4 (260.3–505.0) | 465.2 (196.6–1790.4) | 0.474 |
| Data are presented as the mean±SD, median (range, minimum-maximum), or n (%). Significant P values are in bold type. HLA – human leukocyte antigen; TBI – total body irradiation; aGVHD – acute graft-versus-host disease; CMV – cytomegalovirus; EBV – Epstein-Barr virus; LDH – lactate dehydrogenase; TBIL – total bilirubin; AML – acute myeloblastic leukemia; ALL – acute lymphoblastic leukemia; CML – chronic myelogenous leukemia; MDS – myelodysplastic syndrome; AA – aplastic anemia; BU – busulfan; CY – cyclophosphamide; ATG – anti-thymocyte globulin; Flu – fludarabine; Haplo – haploidentical; MRD – matched related donor; MUD – matched unrelated donor; GI – gastrointestinal; Hb – hemoglobin; PLT – platelet. | |||